<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>PDUFA</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>LHON updates: Gene therapy progress; idebenone receives US CRL </title>
      <description>
        <![CDATA[Chiesi Group’s idebenone faced a regulatory setback last month after the U.S. FDA issued a complete response letter (CRL) to the company’s NDA for Leber hereditary optic neuropathy (LHON), a rare inherited disorder that causes sudden vision loss.But a chance missed for Chiesi may be an opportunity for gene therapies, including Gensight Biologics SA’s lenadogene nolparvovec (Lumevoq; GS-010).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730074</guid>
      <pubDate>Thu, 02 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730074-lhon-updates-gene-therapy-progress-idebenone-receives-us-crl</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eya-and-DNA-illustration.webp?t=1658513444" type="image/png" medium="image" fileSize="350713">
        <media:title type="plain">Eye and DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Workload reductions figure into FDA’s FY2026 user fees</title>
      <description>
        <![CDATA[While inflation in the U.S. is hovering below 3%, increases in some FDA user fees for fiscal 2026 are tripling that rate. PDUFA fees for branded prescription drugs and biological products will see a 9% hike come Oct. 1, and the increase in MDUFA fees will more than double the inflation rate with a 7% hike across the board.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722783</guid>
      <pubDate>Mon, 04 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722783-workload-reductions-figure-into-fdas-fy2026-user-fees</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-dollar-sign-on-white-background.webp?t=1721252292" type="image/jpeg" medium="image" fileSize="39433">
        <media:title type="plain">Blue dollar sign on white background</media:title>
      </media:content>
    </item>
    <item>
      <title>Adcom agrees with FDA: Otsuka’s PTSD treatment needs more study</title>
      <description>
        <![CDATA[In a 10-1 vote, the U.S. FDA’s Psychopharmacologic Drugs Advisory Committee said Otsuka Pharmaceutical Co. Ltd.’s studies of its combination post-traumatic stress disorder (PTSD) treatment did not show enough efficacy. Had the adcom felt otherwise, the path may have been smoother for a new treatment in an indication that hasn’t seen regulatory advancement in decades. The committee’s conclusion, however, is not binding on the FDA, which will make its own decision whether to approve.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722456</guid>
      <pubDate>Tue, 22 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722456-adcom-agrees-with-fda-otsukas-ptsd-treatment-needs-more-study</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Rexulti.webp?t=1752873562" type="image/png" medium="image" fileSize="308088">
        <media:title type="plain">Rexulti</media:title>
      </media:content>
    </item>
    <item>
      <title>Adcom agrees with FDA: Otsuka’s PTSD treatment needs more study</title>
      <description>
        <![CDATA[In a 10-1 vote, the U.S. FDA’s Psychopharmacologic Drugs Advisory Committee said Otsuka Pharmaceutical Co. Ltd.’s studies of its combination post-traumatic stress disorder (PTSD) treatment did not show enough efficacy. Had the adcom felt otherwise, the path may have been smoother for a new treatment in an indication that hasn’t seen regulatory advancement in decades. The committee’s conclusion, however, is not binding on the FDA, which will make its own decision whether to approve.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722265</guid>
      <pubDate>Fri, 18 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722265-adcom-agrees-with-fda-otsukas-ptsd-treatment-needs-more-study</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Rexulti.webp?t=1752873562" type="image/png" medium="image" fileSize="308088">
        <media:title type="plain">Rexulti</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA wants more data for Otsuka’s sNDA in PTSD</title>
      <description>
        <![CDATA[The U.S. FDA is insisting that another study is needed to bolster the sNDA for Rexulti (brexpiprazole) from Otsuka Pharmaceutical Co. Ltd. in treating adults with post-traumatic stress disorder (PTSD). The agency’s Psychopharmacologic Drugs Advisory Committee and the company, one of Japan’s biggest pharmas, will discuss this during July 18’s adcom hearing regarding the efficacy of Rexulti in combination with sertraline.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722161</guid>
      <pubDate>Wed, 16 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722161-fda-wants-more-data-for-otsukas-snda-in-ptsd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Military-PTSD-neuro-psych.webp?t=1696861063" type="image/jpeg" medium="image" fileSize="223452">
        <media:title type="plain">Woman  in military clothing talking with psychologist</media:title>
      </media:content>
    </item>
    <item>
      <title>Split adcom vote not what Urogen envisioned</title>
      <description>
        <![CDATA[More telling than the U.S. FDA’s Oncologic Drugs Advisory Committee’s 4-5 vote May 21 on the overall benefit-risk of Urogen Pharma Inc.’s UGN-102 (mitomycin) is that the panel’s urology specialists and the patient representative all voted yes, saying the drug would be an important alternative to what is often a continuing cycle of surgery for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720349</guid>
      <pubDate>Wed, 21 May 2025 16:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720349-split-adcom-vote-not-what-urogen-envisioned</link>
    </item>
    <item>
      <title>Street a bit uneasy ahead of Urogen adcom</title>
      <description>
        <![CDATA[With a PDUFA date less than four weeks away, Urogen Pharma Inc. has been having a rough ride on the Street since the U.S. FDA released a joint briefing document for the May 21 Oncologic Drugs Advisory Committee meeting on UGN-102 (mitomycin).]]>
      </description>
      <guid>http://www.bioworld.com/articles/720322</guid>
      <pubDate>Mon, 19 May 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720322-street-a-bit-uneasy-ahead-of-urogen-adcom</link>
    </item>
    <item>
      <title>PDUFA date miss another disappointing delay for Barth drug</title>
      <description>
        <![CDATA[Stealth Biotherapeutics Inc., and, more importantly, patients with Barth syndrome, faced another disappointing delay April 29 when the U.S. FDA kicked its approval decision down the road for Stealth’s elamipretide.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719679</guid>
      <pubDate>Tue, 29 Apr 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719679-pdufa-date-miss-another-disappointing-delay-for-barth-drug</link>
    </item>
    <item>
      <title>US FDA deals second blow to Hengrui-HLB’s liver cancer drug combo</title>
      <description>
        <![CDATA[The U.S. FDA rejected, for the second time, Elevar Therapeutics Inc.’s NDA of a novel combination therapy for advanced liver cancer, which comprised Jiangsu Hengrui Pharmaceutical Co. Ltd.’s PD-1 inhibitor camrelizumab and HLB Co. Ltd.’s small-molecule tyrosine kinase inhibitor, rivoceranib.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718608</guid>
      <pubDate>Tue, 25 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718608-us-fda-deals-second-blow-to-hengrui-hlbs-liver-cancer-drug-combo</link>
    </item>
    <item>
      <title>US FDA deals second blow to Hengrui-HLB’s liver cancer drug combo</title>
      <description>
        <![CDATA[The U.S. FDA rejected, for the second time, Elevar Therapeutics Inc.’s NDA of a novel combination therapy for advanced liver cancer, which comprised Jiangsu Hengrui Pharmaceutical Co. Ltd.’s PD-1 inhibitor camrelizumab and HLB Co. Ltd.’s small-molecule tyrosine kinase inhibitor, rivoceranib.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718404</guid>
      <pubDate>Fri, 21 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718404-us-fda-deals-second-blow-to-hengrui-hlbs-liver-cancer-drug-combo</link>
    </item>
    <item>
      <title>Regeneron starts the week with two CRLs</title>
      <description>
        <![CDATA[The week began with PDUFA-delaying news for Regeneron Pharmaceuticals Inc. The company said it received two complete response letters (CRLs) from the U.S. FDA regarding the priority BLA for its bispecific antibody to treat lymphoma, odronextamab.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706988</guid>
      <pubDate>Mon, 25 Mar 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/706988-regeneron-starts-the-week-with-two-crls</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/08-13-Blog-FDA.webp?t=1628871192" type="image/png" medium="image" fileSize="1092079">
        <media:title type="plain">Magnifying glass, FDA concept image</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA accepts Venatorx NDA for cUTI antibiotic; PDUFA early 2024</title>
      <description>
        <![CDATA[Venatorx Pharmaceuticals Inc. on Aug. 15 said the U.S. FDA accepted its NDA for an intravenous antibiotic combination, cefepime-taniborbactam, to treat complicated urinary tract infection (cUTI), including acute pyelonephritis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/699931</guid>
      <pubDate>Wed, 16 Aug 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699931-fda-accepts-venatorx-nda-for-cuti-antibiotic-pdufa-early-2024</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Urology/Urinary-tract-infection-UTI.webp?t=1671121949" type="image/png" medium="image" fileSize="188476">
        <media:title type="plain">Illustration of infected kidneys, ureter and bladder </media:title>
      </media:content>
    </item>
    <item>
      <title>PDUFA VII keeping pace with the present, prepping for the future</title>
      <description>
        <![CDATA[The PDUFA commitment letter negotiated between industry and the U.S FDA every five years provides an inside look at the future of drug development. The PDUFA VII letter, which is to be presented to Congress by Jan. 15, is no exception.]]>
      </description>
      <guid>http://www.bioworld.com/articles/511849</guid>
      <pubDate>Tue, 28 Sep 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/511849-pdufa-vii-keeping-pace-with-the-present-prepping-for-the-future</link>
    </item>
    <item>
      <title>Provention’s CRL prevents completion of its July 2 PDUFA</title>
      <description>
        <![CDATA[Despite an FDA advisory committee’s narrow ruling that Provention Bio Inc.’s teplizumab has benefits that outweigh the risks in treating diabetes, the agency sent the company a complete response letter (CRL) regarding the diabetes therapy’s priority BLA. The CRL came the evening of July 2, Provention said, the PDUFA date that had been set months before.]]>
      </description>
      <guid>http://www.bioworld.com/articles/509015</guid>
      <pubDate>Tue, 06 Jul 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/509015-proventions-crl-prevents-completion-of-its-july-2-pdufa</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Diabetes/Glucose-monitoring.webp?t=1617996651" type="image/png" medium="image" fileSize="413544">
        <media:title type="plain">Glucose monitoring</media:title>
      </media:content>
    </item>
    <item>
      <title>Athenex specs checked as Oraxol awaits PDUFA date</title>
      <description>
        <![CDATA[Athenex Inc.’s launch of Klisyri (tirbanibulin) likely whetted investor appetite for another prospect coming down the pike: Oraxol, an oral form of paclitaxel for which the Buffalo, N.Y.-based firm has been assigned a PDUFA date of Feb. 28.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503770</guid>
      <pubDate>Thu, 18 Feb 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503770-athenex-specs-checked-as-oraxol-awaits-pdufa-date</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Oral-medication.webp?t=1652383335" type="image/png" medium="image" fileSize="350602">
        <media:title type="plain">Oral medication</media:title>
      </media:content>
    </item>
    <item>
      <title>Still on deck for FDA action, developers continue to wait beyond PDUFAs</title>
      <description>
        <![CDATA[While the FDA’s Center for Drug Evaluation and Research met all action dates for the 53 new molecular entities approved in 2020, despite the COVID-19 pandemic, developers of at least 8 drugs continue to wait for a decision beyond their expected timelines.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503127</guid>
      <pubDate>Tue, 02 Feb 2021 17:32:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503127-still-on-deck-for-fda-action-developers-continue-to-wait-beyond-pdufas</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Calendar-pages.webp?t=1612210132" type="image/png" medium="image" fileSize="448551">
        <media:title type="plain">Calendar pages</media:title>
      </media:content>
    </item>
    <item>
      <title>Still on deck for FDA action, developers continue to wait beyond PDUFAs</title>
      <description>
        <![CDATA[While the FDA’s Center for Drug Evaluation and Research met all action dates for the 53 new molecular entities approved in 2020, despite the COVID-19 pandemic, developers of at least 8 drugs continue to wait for a decision beyond their expected timelines.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503056</guid>
      <pubDate>Tue, 02 Feb 2021 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503056-still-on-deck-for-fda-action-developers-continue-to-wait-beyond-pdufas</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Calendar-pages.webp?t=1612210132" type="image/png" medium="image" fileSize="448551">
        <media:title type="plain">Calendar pages</media:title>
      </media:content>
    </item>
    <item>
      <title>Tsunami of change to challenge PDUFA VII</title>
      <description>
        <![CDATA[Although PDUFA VI still has two years of life left to it, PDUFA VII is already in the birthing process, with the use of real-world data (RWD), AI, and a coming surge of novel cell and gene therapies looking to be prominent features of the next five-year user fee agreement. Politics likely will play a role as well.]]>
      </description>
      <guid>http://www.bioworld.com/articles/496202</guid>
      <pubDate>Thu, 23 Jul 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/496202-tsunami-of-change-to-challenge-pdufa-vii</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Meeting-illustration.webp?t=1595539259" type="image/png" medium="image" fileSize="396838">
        <media:title type="plain">Meeting illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>PDUFA, BsUFA delays could be in the offing</title>
      <description>
        <![CDATA[As the FDA continues to shift its limited resources to the development and review of COVID-19 therapies and vaccines, other drugs in the pipeline may be delayed. In a question-and-answer guidance released late Tuesday, the agency acknowledged that, going forward, it may not be able to sustain its current performance level in meeting all its goal dates for new drugs and biologics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435376</guid>
      <pubDate>Wed, 27 May 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435376-pdufa-bsufa-delays-could-be-in-the-offing</link>
    </item>
  </channel>
</rss>
